Barr Labs settles Cipro antitrust case for $225 million
Send a link to a friend
[January 27, 2017]
(Reuters) - Teva Pharmaceutical
Industries Ltd's Barr Laboratories Inc has reached a $225 million
settlement in an antitrust class action that accused the drugmaker of
keeping a generic version of Bayer AG's antibiotic Cipro off the market,
court documents showed.
The case, which began in 2000 in California state court, centers on
a series of settlements in the late 1990s under which Bayer
allegedly paid Barr Pharmaceuticals, since bought by Teva, $398
million not to market Cipro's generic version. Bayer had earlier
sued Barr claiming that generic Cipro would infringe a Bayer patent.
The plaintiffs, a group of non-profits and individuals in California
who bought Cipro, claimed that the settlement drove up the price of
the drug and violated California's antitrust law and the Cartwright
In December, Teva Pharmaceutical agreed to pay more than $519
million to settle U.S. criminal and civil allegations that the
company bribed overseas officials to gain business for its
The settlement requires an approval from California's highest court.
[to top of second column]
(Reporting by Komal Khettry in Bengaluru; Editing by Amrutha
[© 2017 Thomson Reuters. All rights
Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.